Strata Skin Sciences (SSKN) Getting Somewhat Favorable News Coverage, Accern Reports

News stories about Strata Skin Sciences (NASDAQ:SSKN) have trended somewhat positive recently, according to Accern Sentiment. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Strata Skin Sciences earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned media stories about the medical device company an impact score of 45.0598477788396 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Strata Skin Sciences (SSKN) traded up $0.02 during mid-day trading on Friday, hitting $1.40. The stock had a trading volume of 90,708 shares, compared to its average volume of 102,465. Strata Skin Sciences has a 12-month low of $1.06 and a 12-month high of $5.40. The company has a current ratio of 1.64, a quick ratio of 1.07 and a debt-to-equity ratio of 0.37. The stock has a market cap of $5.62, a PE ratio of -0.19 and a beta of 0.41.

Strata Skin Sciences (NASDAQ:SSKN) last posted its quarterly earnings data on Thursday, November 9th. The medical device company reported ($0.76) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.68) by ($0.08). Strata Skin Sciences had a negative net margin of 56.06% and a negative return on equity of 38.57%. equities analysts forecast that Strata Skin Sciences will post -8.45 earnings per share for the current year.

SSKN has been the topic of a number of analyst reports. HC Wainwright set a $12.00 price objective on Strata Skin Sciences and gave the company a “buy” rating in a research report on Wednesday, October 18th. Zacks Investment Research cut Strata Skin Sciences from a “hold” rating to a “sell” rating in a research report on Thursday, November 16th. Finally, ValuEngine cut Strata Skin Sciences from a “sell” rating to a “strong sell” rating in a research report on Monday, October 2nd.

TRADEMARK VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at

About Strata Skin Sciences

STRATA Skin Sciences, Inc, formerly MELA Sciences, Inc, is a medical technology company. The Company is engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders. The Company has three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging.

Insider Buying and Selling by Quarter for Strata Skin Sciences (NASDAQ:SSKN)

Receive News & Ratings for Strata Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strata Skin Sciences and related companies with's FREE daily email newsletter.

Leave a Reply